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Irinotecan-Cisplatin Therapy for Patients with
Extensive-Stage Small Cell Lung Cancer: Use Patterns
among American Medical Oncologists 2000–2006
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Joanne Willey, RN, OCN,* Michele Andrews, MPH,* and Richard Leff, MD*
Background: Etoposide-platinum doublet therapy has been the
American standard first-line management for patients with small cell
lung cancer for more than a decade. In the 1990s, Japanese inves-
tigators developed a regimen of irinotecan-cisplatin for extensive-
stage patients and, in one head-to-head trial, the irinotecan therapy
produced a statistically significant survival advantage compared
with etoposide and cisplatin. We were interested in how American
oncologists integrate clinical trial data into their current prescribing
practices and studied case-based prescribing recommendations as a
surrogate for current clinical practice. We evaluated Network for
Medical Communications and Research data from 7 years of live
physician meetings to assess changes in use patterns for irinotecan
cisplatin since the initial report of the Japanese clinical trial.
Methods: Data from 38 meetings involving 2174 medical professional
attendees (MD; DO; MD PhD) were reviewed. Attendees were given a
case scenario and asked to select the treatment option that they felt was
most appropriate for the hypothetical setting provided. At each meeting,
responses were collected electronically and immediately displayed to
the attendees. Aggregate response data are held in the Network for
Medical Communications and Research database.
Results: During the 7-year study period, regimens including etoposide
and platinum have consistently been the most frequently recommended
for small cell lung cancer therapy by the meeting participants. The
selection of irinotecan-cisplatin by American oncologists was initially
infrequent, with a modest, transient impact of a plenary session presen-
tation of the Japanese phase III trial data at the 2000 meeting of the
American Society of Clinical Oncology. Publication of the phase III
trial findings in the New England Journal of Medicine in early 2002
stimulated a marked increase in irinotecan-cisplatin prescribing with a
commensurate decrease in the selection of etoposide and cisplatin
therapy. Since 2002, the prescribing patterns have shown an accelerat-
ing return to the use of etoposide and platinum despite continuing study
of irinotecan-platinum regimens.
Conclusions: Statistically significant advantages demonstrated in a
single phase III clinical trial may have only a modest and transient
impact on American oncologists’ prescribing behaviors. Factors
other than the phase III trial results themselves play a role in the
likelihood that prescribing behavior will evolve over time. Corrob-
orating trial data among unambiguously relevant populations will be
necessary to stimulate a change in standard treatment paradigms.
(J Thorac Oncol. 2007;2: 953–956)
INTRODUCTION
In the 1970s and early 1980s, many medical oncolo-
gists were optimistic that small cell lung cancer (SCLC)
would be the next disease to shift to the cure side of the solid
tumor therapeutic ledger. Small cell was an exquisitely
chemo-sensitive neoplasm. There were many available drugs,
each independently active, with differing mechanisms of
action and toxicity profiles, the optimal setting for the devel-
opment of combination therapy strategies. Numerous multi-
agent combinations were tested. Each produced rapid, sub-
stantial, and frequent tumor regression. The strategy of
alternating “non–cross-resistant” regimens, one outgrowth of
the Goldie-Coleman hypothesis, was widely applied. Residual
bulk disease and sanctuary sites were addressed with radiation.
The approach seemed certain to bear therapeutic fruit.1
Unfortunately, SCLC turned out to be far a more resource-
ful opponent than had been hypothesized. The initial three- and
four-drug regimens were active but rarely produced complete
responses. Toxicity was high. Phase III tests of dose intensifi-
cation nearly always failed to improve survival outcomes. Al-
ternating regimens were not superior to the single two-drug
combination of etoposide and cisplatin.2 Adding more drugs to
the etoposide platinum core was also rarely rewarding. Except
for a single European trial adding epirubicin and cyclophosph-
amide to etoposide and cisplatin, which did show a significant
survival advantage compared with etoposide-cisplatin alone3
(but at the expense of a 9% treatment-related death rate), large
phase III trials adding either concurrent paclitaxel4 or sequen-
tial topotecan to etoposide-cisplatin5 or using a tight sequence
of four drugs (the CODE regimen)6 have not improved
survival. Brain failure has been reduced but not eradicated by
prophylactic cranial irradiation,7 and intrathoracic persis-
tence/progression is the rule among patients presenting with
extensive-stage disease.
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Irinotecan was first tested in Japan as a treatment option
for patients with different types of solid tumors. It has
demonstrated activity in colorectal, non-colon gastrointesti-
nal, breast, bladder, and lung cancers, among others.8 Japa-
nese lung cancer investigators have evaluated irinotecan both
as a single agent9 and in combination (IC)10 as treatment for
patients with recurrent SCLC and as combination therapy in
chemo-naı¨ve patients with both extensive and limited disease.
In a phase II Japanese trial, the combination of irinotecan
given at 60 mg/m2 days 1, 8, and 15 plus cisplatin 60 mg/m2
day 1 produced a median overall survival in excess of 12
months in untreated patients, a result numerically superior to
the Japanese experience with etoposide and cisplatin (EC).10
Based on their aggregate phase II experience, Japanese in-
vestigators initiated a phase III trial of IC or EC for patients
with extensive-stage SCLC.11
Initial accrual plans for the Japanese phase III trial were to
enter 230 patients. However, at a preplanned interim analysis, a
statistically significant survival advantage for patients receiving
the IC therapy was seen. This led to ceasing accrual after only
154 total patients were entered. Study data were presented at the
American Society of Clinical Oncology meeting in the spring of
200012 and published in The New England Journal of Medicine
approximately 19 months later.11 To confirm the efficacy of the
IC regimen in non-Japanese patients, two North American trials
comparing IC and EC were launched soon after the Japanese
data were reported. One was identical in treatment dose and
schedule to the Japanese trial, whereas the other used a modified
21-day treatment regimen. Preliminary toxicity profiles from the
study comparing every 21-day treatment regimens for IC and
EC were presented at the ASCO 2003 annual meeting.13 The
every-3-week IC regimen was at least as well tolerated as the
every-4-week schedule (no grade 4 diarrhea), and dose intensity of
the every-3-week therapy was better than that of the every-4-week
treatment reported among Japanese patients. The final results of this
trial were presented at ASCO in 2005, with reduced hematologic
toxicity but no survival benefit for patients on the IC versus the EC
arm.14 Mature trial data have recently been published.15
METHODS
The Analytics Group of the Network for Medical Com-
munication and Research has a long-standing interest in
understanding how American medical oncologists use re-
search data to drive their daily management of patients seen
in clinical practice. Since 2000, we have used case-based
methodology and anonymous audience response technolo-
gies16 to evaluate treatment approaches available to American
medical oncologists for patients with lung cancer. In partic-
ular, we assessed their plans for the use of etoposide and
platinum and irinotecan-platinum regimens in patients with
previously untreated extensive-stage SCLC. During this time,
we accumulated research responses from more than 1700
physicians. The data from 2004 to 2006 are particularly
robust, as our lung cancer research program expanded to a
total of 16 meetings during that time.
RESULTS
Meeting data for the years 2000 to 2006 are shown in
Table 1. Demographics of the physician participants in the
research sessions held from 2004 to 2006 are shown in Table 2.
Data concerning plans by American oncologists to use an
irinotecan-platinum regimen as first-line therapy are shown in
Table 3 and Figure 1. Two patterns are evident in these data: the
increase and decrease of interest in the IC regimen and the
persisting split between advocates of cisplatin and carboplatin
for the management of patients with extensive-stage SCLC.
Until 2002, use of first-line irinotecan-based therapy was un-
common among American oncologists despite the availability of
published phase II data and the ASCO plenary presentation and
associated published abstract. However, the power of a New
England Journal publication can be gauged by the spike in
planned use recorded in the 2002 research year. Perhaps not
surprisingly (at least in retrospect), much of the increase in planned
IC use seems to have occurred among previous EC users.
In 2003 to 2004, while American oncologists awaited
outcome data from the confirmatory trials, use of the IC regimen
ebbed only modestly, mostly in favor of renewed preference for
use of EC. In June 2005, the initial outcome data from one of the
confirmatory trials of EC versus IC were presented at ASCO.14
There was no evidence of a survival benefit from the adminis-
tration of an every-3-week IC regimen. However, the toxicity
profile of the IC regimen differed from that of EC, with several
relevant grade 3 or 4 toxicities other than diarrhea favoring IC
therapy. Still, after this report, a clear decrease in IC usage
occurred, despite the generally favorable toxicity profile with IC
treatment. In 2006, planned first-line use of IC for patients with
extensive-stage SCLC has essentially returned to baseline. Data
from the second confirmatory trial are still pending.
DISCUSSION
Over the past 3 decades, progress toward better therapy
for patients with SCLC has been slow. This has been partic-
ularly true when the target population of interest has exten-
sive-stage disease. Large-scale trials adding new agents, se-
quencing active regimens, and intensifying drug doses have
been mostly unrewarding. For most patients, a partial re-
sponse to initial therapy is followed by disease progression
and minimal benefit from salvage therapies. The median
survival expectation for a patient with extensive-stage disease
at the beginning of therapy is less than 1 year.
Randomized controlled phase III clinical trial data are
powerful drivers of treatment selection by American oncolo-
gists. Solid tumor clinical trials performed by recognized inves-
tigators and research groups that show a survival benefit for a
new therapy are routinely reported at international meetings
TABLE 1. Research Participants 2000–2006
Year Meetings Research Participants
2000 5 201
2001 2 69
2002 4 268
2003 3 128
2004 9 424
2005 8 559
2006 7 525
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such as ASCO. These reports are essentially always followed by
manuscript publication in a widely read, peer-reviewed journal.
For phase II trials, oral session presentations are less assured, but
reports are routinely presented as posters or published abstracts.
Although manuscripts detailing such phase II work are often
easier to generate and publish than multi-center phase III trial
reports, they may have less impact on physician practice, espe-
cially if the phase II data are from investigators and research
groups outside the United States, except for a relatively small
circle of well-known international centers. Still, these phase II
studies can support off–label use of commercially available
chemotherapeutics in the United States, where reimbursement is
commonly assured if there is a data-driven compendium listing
to support the treatment approach.
The utility of irinotecan as single-agent therapy for pa-
tients with relapsed or refractory SCLC was reported in the
widely ready Journal of Clinical Oncology by Masuda and
colleagues in 1992.9 A follow-up article in Journal of Clinical
Oncology by Kudoh10 reporting efficacy for combination IC was
published 6 years later. The impact of these initial reports on
plans among American oncologists for first-line therapy among
patients with extensive-stage SCLC was modest. The ASCO
plenary presentation of the Japanese IC versus EC trial occurred
in June 2000.11 Even this event did not seem to alter American
oncology practice in a numerically important way (caution is
needed here because the sample size of respondents for 2001 is
the smallest of any full year studied). The New England Journal
report by Noda et al.12 of their experience with IC was published
in January 2002, before the first NMCR meeting held that year
in which therapy choices in small cell lung cancer were studied.
This publication of the full manuscript in a very widely read,
high-impact journal did influence a substantial segment of prac-
ticing American oncologists, especially those who had already
been using cisplatin-based therapy for this indication.
There are other recent examples of rapid adoption of
specific cancer treatment regimens based on the results of a
FIGURE 1. Rise and fall of Irinotecan.
TABLE 2. Demographic Characteristics of Physician Participants*
Region of the US:
Northeast 26% Southeast 19% Central 26% Southwest 12% West 18%
Time since completion of training:
5 years 28% 5–10 years 19% 11–20 years 23% 20 years 30%
Practice size:
Solo 20% 2–5 39% 6–10 17% 10 24%
Gender:
Female 22% Male 78%
Practice setting:
Academic or teaching
institution 27%
Community 73%
* Network for Medical Communications and Research meetings Lung and Oncology Series 2005–2006; N  1508.
TABLE 3. Treatment Selection from Options Provided
Etoposide-
cisplatin
Irinotecan-
cisplatin
Etoposide-
carboplatin
Three
Drugs Other
2000 37 9 49 3 3
2001 47 4 40 8 1
2002 26 29 38 7 0
2003 35 25 36 4 0
2004 33 23 42 2 1
2005 36 15 44 4 1
2006 39 6 49 5 1
Data presented as percentages.
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single pivotal phase III trial.17,18 For example, the regimen of
weekly irinotecan, 5 FU, and leucovorin (IFL) supplanted 5FU/
leucivorin (5FU/LV) alone as a standard first-line therapy for
American patients with advanced colorectal cancer based on the
work of Saltz et al. published in the New England Journal of
Medicine in 2000.17 Findings from this three-arm trial included
a significant survival advantage for IFL therapy compared with
5FU/LV. In addition, grade 4 neutropenia and neutropenic fever
were actually less frequent with IFL than the comparator. How-
ever, subsequent studies have shown inferior efficacy for this
bolus IFL regimen compared with combination regimens based
on infusion 5 FU, leading to a subsequent decrease in IFL
usage.19 The driver of decreased IFL use as first-line therapy in
colon cancer patients is therefore substantially different from the
situation of IC in SCLC. In the latter case, there is no data-driven
basis for the move away from IC but rather simply the failure of
a subsequent trial with a slightly variant schedule to corroborate
the initial findings of a survival advantage.
The Cochrane Effective Practice and Organization of Care
Group has evaluated the various methodologies used for the
promotion of certain treatments by physicians.20 Methods that
were found to be effective included educational outreach visits,
reminders or prompts, and interactive educational meetings. A
lesser degree of efficacy was seen with the use of local opinion
leaders. Didactic meetings had little effect on physician use of a
certain treatment. The absence of effect of the ASCO presenta-
tion on prescribing patterns supports the Effective Practice and
Organization of Care Group findings of limited effectiveness of
didactic educational symposia in altering use patterns. However,
publication of the data in New England Journal of Medicine
likely led to in an increase in both individual physician aware-
ness of the data and an increase in opinion leaders discussing the
role of irinotecan at various interactive meetings.
From 2003 to 2006, trends suggest initial patience on the
part of physicians to “stay the course” once they have made an
evidence-based change in a first-line treatment approach. Given
that behavior, one may think that physicians who did make a
change from EC to IC after the Noda report might have felt that
the failure of an every-3-week IC schedule to also show a
survival advantage over an EC doublet was interesting but not
really relevant. They could have easily justified continuing to
use the well-tolerated IC regimen while waiting for the findings
from the second confirmatory trial as an intellectually sound
strategy. However, that is not what happened. Instead, plans for
IC use declined substantially after the report of the American
trial and were replaced once again by etoposide-based therapy.
As of 2005, EC use was the preference of almost half of all
respondents. Whether a positive result of the still unreported sec-
ond confirmatory trial could shift behavior yet again or whether
American oncologists will function in a “fool me once shame on
thee, fool me twice shame on me” fashion remains to be seen.
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